Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study

References

• WHO. 2014. Chronic lymphocytic leukemia – Union for International Cancer Control – Review of Cancer Medicines on the WHO List of Essential Medicines.
   Google Scholar
• Monnereau A, Remontet L, Maynadié M, et al. Estimation nationale de l’incidence des cancers en france entre 1980 et 2012. Partie 2 – hémopathies malignes. Saint-Maurice (France): Institut de veille sanitaire; 2013. p. 88. French.
   Google Scholar
• Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;2:vi50–vi54.
   Google Scholar
• Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312:2265–2276.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Delgado J, Baumann T, Ghita G, et al. Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy. Curr Pharm Des. 2012;18:3356–3362.
   PubMed Web of Science ®Google Scholar
• Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma – novel and emerging therapies. Cancer Manag Res. 2013;5:251–269.
   PubMedGoogle Scholar
• Smolewski P, Witkowska M, Korycka-Wolowiec A. New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. ISRN Oncol. 2013;2013:740615.
   PubMedGoogle Scholar
• Gribben JG. Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther. 2010;10:1389–1394.
   PubMed Web of Science ®Google Scholar
• Aurrant T, Callet-Bauchu E, Cymbalista F, et al. Recommandations 2012 de la SFH pour le diagnostic, le traitement et le suivi de la leucémie lymphoïde chronique. Hématologie. 2013;19(supplement 1):4–9. French.
   Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v78–v84.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–1765.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011;118:2085–2093.
   PubMed Web of Science ®Google Scholar
• Knauf W, Abenhardt W, Dörfel S, et al. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haemologists in Germany-data from the prospective Tumor Registry Lymphatic Neoplasms (TLN). Hematol Oncol. 2015;33:15–22. 638–644.
   PubMed Web of Science ®Google Scholar
• Satram-Hoang S, Reyes C, Hoang KQ, et al. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol. 2014;93:1335–1344.
   PubMed Web of Science ®Google Scholar
• Shah N, Tam C, Seymour JF, et al. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? Leuk Lymphoma. 2015;56:1599–1610.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24:1575–1581.
   PubMed Web of Science ®Google Scholar
• Terschüren C, Gierer S, Brillant C, et al. Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany? Ann Oncol. 2010;21:2045–2051.
   PubMed Web of Science ®Google Scholar
• Smolej L. Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. Curr Pharm Des. 2012;18:3399–3405.
   PubMed Web of Science ®Google Scholar
• Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015;75:143–155.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute – Chronic lymphocytic leukemia treatment (PDQ®) 2015. NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Non-Hodgkin’s Lymphomas. Version 1.2015 [Internet]. 2015 [cited 2015 Feb 10]; Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nhl.
   Google Scholar
• Cramer P, Fink AM, Busch R, et al. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leuk Lymphoma. 2013;54:1821–1822.
   PubMed Web of Science ®Google Scholar
• Fornecker LM, Aurran-Schleinitz T, Michallet AS, et al. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: *the French intergroup experience. Am J Hematol. 2015;90:511–514.
   PubMed Web of Science ®Google Scholar
• Cuthill K, Devereux S. How I treat patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2013;163:423–435.
   PubMed Web of Science ®Google Scholar
• Cramer P, Isfort S, Bahlo J, et al. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse-therapies: a meta-analysis of five prospective trials by the German CLL study group (GCLLSG). Haematologica. 2015;100:1451–1459.
   PubMed Web of Science ®Google Scholar
• Meunier G, Ysebaert L, Nguyen-Thi PL, et al. First line chronic lymphocytic leukemia immunochemotherapy for the elderly patients over 79 years is feasible, and achieves good results: a FILO retrospective study. Blood. 2015;126:4170.
   Google Scholar
• Zenz T, Gribben JG, Hallek M, et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012;119:4101.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014;124:3059–3064.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Ma S, Brander D, et al. Venetoclax (abt-199/gdc-0199) combined with rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia. EHA Learning Center 2015. Abstract: S431.
   Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): first results from a randomized, double-blind, placebo-controlled, phase III study. ASCO Annual Meeting 2015. J Clin Oncol. 2015;33. (Suppl; abstr LBA7005).
   Web of Science ®Google Scholar
• Zelenetz AD, Robak T, Coiffier B, et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. Blood. 2015;126:LBA-5.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Sciumè M, Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia. 2014;28:642–648.
   PubMed Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124:2196–202.
   PubMed Web of Science ®Google Scholar
• Leblond V, Dilhuydy MS, Foà R, et al. Preliminary safety data from the phase 3b green study of obinutuzumab (G) alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL) [abstract]. EHA Learning Center. 2016;135183.
   Google Scholar
• Van Oers MH, Kuliczkowski K, Smolej L, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukemia (PROLONG): an open-label, multicentre, randomized phase 3 study. Lancet Oncol. 2015;16:1370–1379.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–3566.
   PubMed Web of Science ®Google Scholar
• Masse V, Al Jijakli A, Genet P, et al. Screening and management of hepatitis B virus before the first rituximab infusion: we must do better! Ash 2014; No. 2754.
   Google Scholar
• Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–3743.
   PubMed Web of Science ®Google Scholar